查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179737

皮肤癌治疗市场：按类型、疗法、分销渠道分类：2021-2031 年全球机会分析和行业预测

Skin Cancer Treatment Market By Type, By Therapy, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 251 Pages | 商品交期: 2-3个工作天内

价格

皮肤癌是一种常见的癌症，由太阳的有害辐射引起。

暴露在阳光下的皮肤会出现异常色素沉着、胶原病、皮肤皱纹和光化性角化病等迹象。 皮肤癌有两种类型：黑色素瘤和非黑色素瘤。 非黑色素瘤有两种类型：基底细胞癌和鳞状细胞癌，基底细胞癌称为鳞状细胞癌，鳞状细胞癌称为非黑色素瘤。 非黑色素瘤皮肤癌是人类最常见的皮肤癌类型，影响全球超过 2-3 百万人。 皮肤癌有靶向治疗、化疗、免疫治疗等药物治疗。

全球范围内非黑色素瘤和黑色素瘤类型皮肤癌的患病率不断上升，各种皮肤癌治疗方法的可用性，以及对皮肤癌治疗的需求不断增加，正是这些因素影响皮肤癌生长的原因癌症治疗市场。 例如，根据美国癌症协会的数据，到 2020 年，美国每年将有 540 万人被诊断出患有基底膜癌和鳞状细胞癌，并且将有 2,000 人死于同一种癌症。 据估计，美国有 330 万人患有基底膜癌和鳞状细胞癌。 基底细胞癌是美国人最常见的皮肤癌类型，每 10 人中就有 8 人受到影响。 鳞状细胞癌在美国人中并不常见。 此外，政府为控制皮肤癌而采取的举措以及参与製造和开发有效皮肤癌治疗的先进疗法的主要参与者推动了皮肤癌治疗市场。这是一个因素 例如，2020年诺华公司宣布了其产品Tafinlar+Mekinist治疗III期BRAF V600突变黑色素瘤患者的COMBI-AD临床试验，并已证明对那些癌症復发高风险患者有效。提供有针对性和长期的影响。 此外，医院药房和药品、诊断中心、医院等的可用性也会影响市场增长。 然而，与使用化学疗法和放射疗法治疗皮肤癌相关的副作用正在抑制市场增长。 越来越多的产品批准和治疗皮肤癌的先进疗法的出现为市场增长提供了机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析
  • 专利情况

第 4 章皮肤癌治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 黑色素瘤
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 非黑色素瘤
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
    • 非黑色素瘤皮肤癌治疗市场：按类型分类
      • 基底细胞癌市场规模和预测：按地区
      • 鳞状细胞癌市场规模和预测：按地区
      • 其他市场规模和预测：按地区

第 5 章皮肤癌治疗市场：按治疗分类

  • 概览
    • 市场规模和预测
  • 免疫疗法
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 靶向药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 化疗
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章皮肤癌治疗市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模/预测：按地区
    • 市场分析：按国家/地区分类
  • 药店、零售药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 在线提供商
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章皮肤癌治疗市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按类型
      • 北美非黑色素瘤皮肤癌治疗市场：按类型分类
    • 北美市场规模和预测：按处理方法
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按类型
      • 欧洲非黑色素瘤皮肤癌治疗市场：按类型分类
    • 欧洲市场规模和预测：按处理方法
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太市场规模和预测：按类型
      • 亚太地区非黑色素瘤皮肤癌治疗市场：按类型分类
    • 亚太地区市场规模和按处理方法预测
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按类型
      • LAMEA 非黑色素瘤皮肤癌治疗市场：按类型分类
    • LAMEA 市场规模和预测：按处理方法
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • Amgen Inc.
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Glaxosmithkline plc
  • LEO Pharma
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
Product Code: A17526

Skin cancer is common type of cancer caused due to sun's harmful radiation. The abnormal pigmentation, collagenosis, skin wrinkling, and solar keratosis on sun-exposed skin are the signs associated with skin cancer. There are two types of skin cancers including melanoma and non-melanoma. There are two types of non-melanoma cancers which includes basal cell carcinoma and squamous cell carcinoma. Non-melanocytic skin cancer is the most prevalent type of skin cancer detected in people which affects over 2-3 million people worldwide. There are several medicated treatments available for skin cancer which includes targeted therapy, chemotherapy, and immunotherapy.

Increase in prevalence of non-melanoma and melanoma type of skin cancer across the globe, availability of various skin cancer treatments, and increased demand for skin cancer treatment are the factors that positively influence the skin cancer treatment market growth. For instance, according to the American Cancer Society, in 2020, 5.4 million people were diagnosed with basal and squamous skin cancer in the U.S. each year and there are 2,000 people die with same cancer. As per the same source, estimated number of people suffering from basal and squamous skin cancer in U.S. is 3.3 million. The most common type of skin cancer frequently observed in American people is basal cell cancer with 8 out of 10 people.  Squamous cell cancer is less likely observed in American people. In addition, initiatives taken by governments for the management of skin cancer and key players involved in the manufacturing and development of the advanced therapies for the effective skin cancer treatment are the factor boost skin cancer treatment market. For instance, in 2020, Novartis AG announced COMBI-AD clinical trial for the products Tafinlar + Mekinist to treat stage III BRAF V600-mutated melanoma patients to provide surgery to provide efficient, long-term effect for those patients who have high risk of cancer recurrence. In addition, availability of hospital pharmacies and drugs, diagnostic centers and hospitals influence the market growth. However, side effects associated with use of chemotherapy and radiotherapy skin cancer treatment restrain the market growth. Rise in number of product approvals and emergence of advanced therapies for skin cancer treatment are opportunities for the market growth.

The global skin cancer treatment market is segmented on the basis of type, therapy, distribution channel, and region. By type, the market is classified into melanoma and non-melanoma. The non-melanoma segment is further segmented into basal cell carcinoma, squamous cell carcinoma, and others. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global skin cancer treatment market are Amgen Inc, Bristol Myers Squibb Company, F. Hoffman-La-Roche Ltd, GlaxoSmithKline Plc., LEO Pharm A/S, Merck KGAA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals and, Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin cancer treatment market analysis from 2021 to 2031 to identify the prevailing skin cancer treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the skin cancer treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global skin cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Type

  • Melanoma
  • Non-Melanoma
    • Type
    • Basal Cell Carcinoma
    • Squamous Cell Carcinoma
    • Others

By Therapy

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Amgen Inc.
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche
    • Glaxosmithkline plc
    • LEO Pharma
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: SKIN CANCER TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Melanoma
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Non-Melanoma
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type
      • 4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region
      • 4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region
      • 4.3.4.3 Others Market size and forecast, by region

CHAPTER 5: SKIN CANCER TREATMENT MARKET, BY THERAPY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Immunotherapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Targeted Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Chemotherapy
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: SKIN CANCER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.2.3 North America Market size and forecast, by Therapy
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Therapy
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Therapy
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Therapy
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.3.3 Europe Market size and forecast, by Therapy
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Therapy
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Therapy
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Therapy
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Therapy
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Therapy
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Therapy
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Therapy
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Therapy
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Therapy
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Therapy
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Therapy
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Therapy
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Therapy
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Therapy
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Therapy
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Therapy
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Therapy
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Therapy
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Amgen Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bristol-Myers Squibb
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 F. Hoffmann-La Roche
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Glaxosmithkline plc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 LEO Pharma
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Merck KGaA
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novartis AG
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Pfizer Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Regeneron Pharmaceuticals, Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Sun Pharmaceutical Industries Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. SKIN CANCER TREATMENT MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. SKIN CANCER TREATMENT MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. SKIN CANCER TREATMENT MARKET, FOR NON-MELANOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. SKIN CANCER TREATMENT MARKET FOR NON-MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 7. SKIN CANCER TREATMENT MARKET, FOR BASAL CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. SKIN CANCER TREATMENT MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. SKIN CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 11. SKIN CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. SKIN CANCER TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. SKIN CANCER TREATMENT MARKET, FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. SKIN CANCER TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. SKIN CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. SKIN CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. GLOBAL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 18. SKIN CANCER TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. SKIN CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. SKIN CANCER TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. SKIN CANCER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. SKIN CANCER TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. SKIN CANCER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. SKIN CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. U.S. SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. U.S. SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 32. U.S. SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. CANADA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. CANADA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 35. CANADA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. MEXICO SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. UK SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. UK SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 52. UK SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ITALY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. ITALY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 55. ITALY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. CHINA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. CHINA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 72. CHINA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. INDIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. INDIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 75. INDIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 76. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 102.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 103.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 104.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 105.AMGEN INC.: NET SALES,
  • TABLE 106.AMGEN INC.: KEY STRATERGIES
  • TABLE 107.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 108.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 109.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 110.BRISTOL-MYERS SQUIBB: NET SALES,
  • TABLE 111.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
  • TABLE 112.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 113.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 114.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 115.F. HOFFMANN-LA ROCHE: NET SALES,
  • TABLE 116.F. HOFFMANN-LA ROCHE: KEY STRATERGIES
  • TABLE 117.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 118.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 119.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 120.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 121.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 122.LEO PHARMA: COMPANY SNAPSHOT
  • TABLE 123.LEO PHARMA: OPERATING SEGMENTS
  • TABLE 124.LEO PHARMA: PRODUCT PORTFOLIO
  • TABLE 125.LEO PHARMA: NET SALES,
  • TABLE 126.LEO PHARMA: KEY STRATERGIES
  • TABLE 127.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 128.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 129.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 130.MERCK KGAA: NET SALES,
  • TABLE 131.MERCK KGAA: KEY STRATERGIES
  • TABLE 132.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 133.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 134.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 135.NOVARTIS AG: NET SALES,
  • TABLE 136.NOVARTIS AG: KEY STRATERGIES
  • TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140.PFIZER INC.: NET SALES,
  • TABLE 141.PFIZER INC.: KEY STRATERGIES
  • TABLE 142.REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 143.REGENERON PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 144.REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 145.REGENERON PHARMACEUTICALS, INC.: NET SALES,
  • TABLE 146.REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 147.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 148.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 149.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 150.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  • TABLE 151.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.SKIN CANCER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.SKIN CANCER TREATMENT MARKET,2021-2031
  • FIGURE 3.SKIN CANCER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.SKIN CANCER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.SKIN CANCER TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NON-MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.SKIN CANCER TREATMENT MARKET,BY THERAPY,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.SKIN CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.SKIN CANCER TREATMENT MARKET BY REGION,2021
  • FIGURE 26.U.S. SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.UK SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.JAPAN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.CHINA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.AUSTRALIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH KOREA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SOUTH AFRICA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF LAMEA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49.COMPETITIVE DASHBOARD
  • FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 51.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 52.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
  • FIGURE 53.F. HOFFMANN-LA ROCHE.: NET SALES ,($MILLION)
  • FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 55.LEO PHARMA.: NET SALES ,($MILLION)
  • FIGURE 56.MERCK KGAA.: NET SALES ,($MILLION)
  • FIGURE 57.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 58.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 59.REGENERON PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
  • FIGURE 60.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)